Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation-Reference-Cited by-同舟云学术

Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation

Published:2018-11-27 Issue:3 Volume:33 Page:211-221
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Hosono Makoto^ORCID,Ikebuchi Hideharu,Nakamura Yoshihide,Yanagida Sachiko,Kinuya Seigo

Funder

Bayer Yakuhin

Japanese Society of Nuclear Medicine

Japan Radioisotope Association

Eisai

Fujifilm

Fujifilm RI Pharma

Nihon Medi-Physics

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12149-018-1317-1.pdf

Reference24 articles.

1. ParkerC, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

2. MatsubaraN, et al. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Int J Clin Oncol. 2018;23:173–80.

3. UemuraH, et al. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. Int J Clin Oncol. 2017;22:954–63.

4. Pharmaceuticals and Medical Devices Agency. List of approved products, new drugs; 2018. https://www.pmda.go.jp/files/000213411.pdf . Accessed 22 June 2018.

5. Hosono M. Manual on the proper use of radium-223 dichloride injection in clinical trial. Edition 2. Japanese Society of Nuclear. 2015.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications;Pharmaceuticals;2023-11-17

2. Radiation protection aspects for alpha therapies;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2023-03

3. [²²³Ra] RaCl₂ nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era;Drug Delivery;2022-01-04

4. Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer;Annals of Nuclear Medicine;2021-04-19

5. Clinical Perspectives of Theranostics;Molecules;2021-04-13